Immunization Against Bovine Papillomavirus Infection

Pilacinski, William P.; Glassman, Donald L.; Glassman, Kimberly F.; Reed, David E.; Lum, Melissa A.; Marshall, Richard F.; Muscoplat, Charles C; Faras, Anthony J.

doi:10.1002/9780470513309.ch10

Cited by 31 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A similar effect was obtained with BPV-1 L1 which protected calves against BPV-1 challenge after vaccination [105]. Importantly, only the sera from animals inoculated/immunised with intact virions were capable of neutralising BPV-1 infectivity of murine C127 cells [71].…”

Section: Immunity and Vaccinessupporting

confidence: 57%

Bovine papillomaviruses, papillomas and cancer in cattle

Borzacchiello¹,

Roperto²

2008

Vet. Res.

173

149

View full text Add to dashboard Cite

-Bovine papillomaviruses (BPV) are DNA oncogenic viruses inducing hyperplastic benign lesions of both cutaneous and mucosal epithelia in cattle. Ten (BPV 1-10) different viral genotypes have been characterised so far. BPV 1-10 are all strictly species-specific but BPV 1/2 may also infect equids inducing fibroblastic tumours. These benign lesions generally regress but may also occasionally persist, leading to a high risk of evolving into cancer, particularly in the presence of environmental carcinogenic co-factors. Among these, bracken fern is the most extensively studied. The synergism between immunosuppressants and carcinogenic principles from bracken fern and the virus has been experimentally demonstrated for both urinary bladder and alimentary canal cancer in cows whose diets were based on this plant. BPV associated tumours have veterinary and agricultural relevance in their own right, although they have also been studied as a relevant model of Human papillomavirus (HPV). Recent insights into BPV biology have paved the way to new fields of speculation on the role of these viruses in neoplastic transformation of cells other than epithelial ones. This review will briefly summarise BPV genome organization, will describe in greater detail the functions of viral oncoproteins, the interaction between the virus and co-carcinogens in tumour development; relevant aspects of immunity and vaccines will also be discussed.

show abstract

Section: Immunity and Vaccinessupporting

confidence: 57%

Bovine papillomaviruses, papillomas and cancer in cattle

Borzacchiello¹,

Roperto²

2008

Vet. Res.

173

149

View full text Add to dashboard Cite

show abstract

“…A vaccine prepared with the BPV2 L1 capsid protein produced as a beta-galactosidase fusion protein in Escherichia coli induced the production of neutralizing antibodies and was able to prevent infection [81]. A similar effect was achieved using an E. coli derived BVP1 L1 protein, which protected calves against post-vaccine challenge with a homologous virus [82].…”

Section: Vaccines Against Bpvmentioning

confidence: 91%

Bovine Papillomaviruses — Taxonomy and Genetic Features

Lunardi¹,

Alfieri²,

ArellanoOtonel³

et al. 2013

Current Issues in Molecular Virology - Viral Genetics and Biotechnological Applications

View full text Add to dashboard Cite

“…While the licensed vaccines exclusively target L1 [25], numerous pre-clinical studies have also demonstrated the promise of minor capsid protein L2 as a protective antigen [26–29] and, while controversial, in some studies a therapeutic activity has also been proposed [30, 31]. In this review we describe the potential and status of candidate next-generation HPV vaccines based upon the minor capsid antigen L2 developed with the intent of addressing many of these issues including cost reduction, broader protection including non-genital HPV, fewer doses, stability at ambient temperature and therapeutic efficacy.…”

Section: Remaining Challenges and Scope Of Reviewmentioning

confidence: 99%

Progress and prospects for L2-based human papillomavirus vaccines

Jiang

Schellenbacher

Chackerian

et al. 2016

Expert Review of Vaccines

View full text Add to dashboard Cite

Summary Human papillomavirus (HPV) is a worldwide public health problem, particularly in resource-limited countries. Fifteen high-risk genital HPV types are sexually transmitted and cause 5% of all cancers worldwide, primarily cervical, anogenital and oropharyngeal carcinomas. Skin HPV types are generally associated with benign disease, but a subset is linked to non-melanoma skin cancer. Licensed HPV vaccines based on virus-like particles (VLPs) derived from L1 major capsid antigen of key high risk HPVs are effective at preventing these infections but do not cover cutaneous types and are not therapeutic. Vaccines targeting L2 minor capsid antigen, some using capsid display, adjuvant and fusions with early HPV antigens or Toll-like receptor agonists, are in development to fill these gaps. Progress and challenges with L2-based vaccines are summarized.

show abstract

Immunization Against Bovine Papillomavirus Infection

Cited by 31 publications

References 15 publications

Bovine papillomaviruses, papillomas and cancer in cattle

Bovine papillomaviruses, papillomas and cancer in cattle

Bovine Papillomaviruses — Taxonomy and Genetic Features

Progress and prospects for L2-based human papillomavirus vaccines

Contact Info

Product

Resources

About